Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec;53(12):559-595.
doi: 10.1067/j.cpsurg.2016.11.003. Epub 2016 Nov 29.

Trends and controversies in multidisciplinary care of the patient with breast cancer

Laura S Dominici  1 , Monica Morrow  2 , Elizabeth Mittendorf  3 , Jennifer Bellon  4 , Tari A King  5
Affiliations
Review

Trends and controversies in multidisciplinary care of the patient with breast cancer

Laura S Dominici et al. Curr Probl Surg. 2016 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

I have no conflicts of interest to declare, and the findings presented here have not been published elsewhere.

Figures

Figure 1
Figure 1
Alliance for Clinical Trials in Oncology A11202 trial schema (160). The Alliance A11202 study is a randomized phase III trial that is evaluating the role of ALND in patients with T1–T3 N1 MO breast cancer who have SLN-positive disease after NACT. Specifically, XRT (to the breast or chest wall and nodes) plus ALND is being compared with XRT only in this patient population. ALND, axillary lymph node dissection; BCS, breast-conserving surgery; NACT, neoadjuvant chemotherapy; SLN, sentinel lymph node; XRT, radiotherapy Modified from (114) with permission.
Figure 2
Figure 2
NSABP B-51/RTOG 1304 (NRG 9353) trial schema (161). NRG 9353 is an ongoing randomized phase III clinical trial that is evaluating the role of XRT in patients with documented positive axillary nodes (T1–T3 N1 MO breast cancer) who convert to pathologically node-negative disease after NACT. Specifically, the trial is designed to determine whether patients who undergo BCS can be treated with adjuvant breast XRT alone or require additional nodal XRT, and whether chest-wall and axillary XRT improves outcomes post-mastectomy (versus no XRT). BCS, breast-conserving surgery; ER, estrogen receptor; FNA, fine-need aspirate; NACT, neoadjuvant chemotherapy; NSABP, National Surgical Adjuvant Breast and Bowel Project; pCR, pathological complete response; RTOG, Radiation Therapy Oncology Group; SLNB, sentinel lymph node biopsy; XRT, radiotherapy. Modified from (114) with permission.
See this image and copyright information in PMC

References

    1. Anderson SJ, Wapnir I, Dignam JJ, Fisher B, Mamounas EP, Jeong JH, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol. 2009;27(15):2466–73. - PMC - PubMed
    1. Wapnir IL, Anderson SJ, Mamounas EP, Geyer CE, Jr, Jeong JH, Tan-Chiu E, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol. 2006;24(13):2028–37. - PubMed
    1. Van Zee KJ, Subhedar P, Olcese C, Patil S, Morrow M. Relationship Between Margin Width and Recurrence of Ductal Carcinoma In Situ: Analysis of 2996 Women Treated With Breast-conserving Surgery for 30 Years. Ann Surg. 2015;262(4):623–31. - PMC - PubMed
    1. Azu M, Abrahamse P, Katz SJ, Jagsi R, Morrow M. What is an adequate margin for breast-conserving surgery? Surgeon attitudes and correlates. Ann Surg Oncol. 2010;17(2):558–63. - PMC - PubMed
    1. Morrow M, Jagsi R, Alderman AK, Griggs JJ, Hawley ST, Hamilton AS, et al. Surgeon recommendations and receipt of mastectomy for treatment of breast cancer. JAMA. 2009;302(14):1551–6. - PMC - PubMed

MeSH terms